Regeneron just acquired 23andMe for $256M to weaponize the world’s most valuable genotype-phenotype dataset.
This isn’t a consumer DNA play—it’s a strategic move to compress the timeline from insight to drug. With decades of linked genetic and lifestyle data, 23andMe’s real asset is algorithmic acceleration. Regeneron didn’t buy a brand. They bought time.
This is the moment pharma flipped. Molecules still matter, but now the pipeline begins with data, not a Petri dish. Whoever owns the human code owns the competitive edge.